NO327983B1 - Anvendelse av GABA analoger og et ikke-steroidalt anti-inflammatorisk legemiddel for fremstilling av et medikament for forebyggelse og behandling av gastrointestinal skade - Google Patents

Anvendelse av GABA analoger og et ikke-steroidalt anti-inflammatorisk legemiddel for fremstilling av et medikament for forebyggelse og behandling av gastrointestinal skade Download PDF

Info

Publication number: NO327983B1
Authority: NO; Norway
Prior art keywords: gabapentin; treatment; gaba; drug; ethanol
Prior art date: 1997-08-20

Application number

NO20000786A

Other languages

English (en)

Norwegian (no)

Other versions

NO20000786D0 (no

NO20000786L (no

Inventor

Jr Charles Price Taylor

Antonio Guglietta

Jiayuan Ren

William Patrick Watson

Laurent Diop

Maria Chovet

Lionel Bueno

Hillary J Little

Michael Francis Rafferty

Original Assignee

Warner Lambert Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-08-20

Filing date

2000-02-17

Publication date

2009-11-02

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27369092&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO327983(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2000-02-17 Application filed by Warner Lambert Co filed Critical Warner Lambert Co

2000-02-17 Publication of NO20000786D0 publication Critical patent/NO20000786D0/no

2000-02-17 Publication of NO20000786L publication Critical patent/NO20000786L/no

2009-11-02 Publication of NO327983B1 publication Critical patent/NO327983B1/no

Links

BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical class NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 title claims abstract description 48
238000011282 treatment Methods 0.000 title claims abstract description 33
229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 title claims description 28
239000003814 drug Substances 0.000 title claims description 16
229940079593 drug Drugs 0.000 title claims description 15
239000000041 non-steroidal anti-inflammatory agent Substances 0.000 title claims description 15
230000002265 prevention Effects 0.000 title claims description 4
238000004519 manufacturing process Methods 0.000 title claims description 3
206010061172 Gastrointestinal injury Diseases 0.000 title description 4
UGJMXCAKCUNAIE-UHFFFAOYSA-N Gabapentin Chemical compound OC(=O)CC1(CN)CCCCC1 UGJMXCAKCUNAIE-UHFFFAOYSA-N 0.000 claims abstract description 144
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 109
229960002870 gabapentin Drugs 0.000 claims abstract description 71
AYXYPKUFHZROOJ-ZETCQYMHSA-N pregabalin Chemical compound CC(C)C[C@H](CN)CC(O)=O AYXYPKUFHZROOJ-ZETCQYMHSA-N 0.000 claims abstract description 39
230000002496 gastric effect Effects 0.000 claims abstract description 33
230000006378 damage Effects 0.000 claims abstract description 29
229960001233 pregabalin Drugs 0.000 claims abstract description 20
208000002551 irritable bowel syndrome Diseases 0.000 claims description 11
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 10
208000035475 disorder Diseases 0.000 claims description 8
201000006549 dyspepsia Diseases 0.000 claims description 6
150000003839 salts Chemical class 0.000 claims description 6
206010009900 Colitis ulcerative Diseases 0.000 claims description 3
208000011231 Crohn disease Diseases 0.000 claims description 3
201000006704 Ulcerative Colitis Diseases 0.000 claims description 3
208000022559 Inflammatory bowel disease Diseases 0.000 claims description 2
208000009326 ileitis Diseases 0.000 claims description 2
208000023569 ischemic bowel disease Diseases 0.000 claims description 2
208000007271 Substance Withdrawal Syndrome Diseases 0.000 abstract description 6
206010048010 Withdrawal syndrome Diseases 0.000 abstract description 6
241001465754 Metazoa Species 0.000 description 40
230000000694 effects Effects 0.000 description 36
CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 35
241000700159 Rattus Species 0.000 description 25
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 22
241000699670 Mus sp. Species 0.000 description 20
NHJVRSWLHSJWIN-UHFFFAOYSA-N 2,4,6-trinitrobenzenesulfonic acid Chemical compound OS(=O)(=O)C1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O NHJVRSWLHSJWIN-UHFFFAOYSA-N 0.000 description 19
230000000112 colonic effect Effects 0.000 description 19
229960000905 indomethacin Drugs 0.000 description 17
WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 16
150000001875 compounds Chemical class 0.000 description 15
239000007924 injection Substances 0.000 description 15
238000002347 injection Methods 0.000 description 15
238000012360 testing method Methods 0.000 description 15
208000002193 Pain Diseases 0.000 description 13
238000002360 preparation method Methods 0.000 description 13
238000007912 intraperitoneal administration Methods 0.000 description 12
238000005259 measurement Methods 0.000 description 12
230000037040 pain threshold Effects 0.000 description 12
230000003187 abdominal effect Effects 0.000 description 11
239000002158 endotoxin Substances 0.000 description 11
238000002474 experimental method Methods 0.000 description 11
229920006008 lipopolysaccharide Polymers 0.000 description 11
206010010904 Convulsion Diseases 0.000 description 10
230000003902 lesion Effects 0.000 description 10
230000036407 pain Effects 0.000 description 10
208000009935 visceral pain Diseases 0.000 description 10
208000018522 Gastrointestinal disease Diseases 0.000 description 9
208000004454 Hyperalgesia Diseases 0.000 description 9
208000000114 Pain Threshold Diseases 0.000 description 9
230000006399 behavior Effects 0.000 description 9
239000011780 sodium chloride Substances 0.000 description 9
210000001072 colon Anatomy 0.000 description 8
230000036461 convulsion Effects 0.000 description 8
239000000243 solution Substances 0.000 description 8
230000008602 contraction Effects 0.000 description 7
-1 idomethacin Chemical compound 0.000 description 7
230000009467 reduction Effects 0.000 description 7
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
206010053552 allodynia Diseases 0.000 description 6
238000003556 assay Methods 0.000 description 6
235000005911 diet Nutrition 0.000 description 6
230000037213 diet Effects 0.000 description 6
238000011835 investigation Methods 0.000 description 6
BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 6
230000004044 response Effects 0.000 description 6
239000003981 vehicle Substances 0.000 description 6
208000027418 Wounds and injury Diseases 0.000 description 5
230000001684 chronic effect Effects 0.000 description 5
230000010339 dilation Effects 0.000 description 5
230000001965 increasing effect Effects 0.000 description 5
208000014674 injury Diseases 0.000 description 5
230000006742 locomotor activity Effects 0.000 description 5
238000000034 method Methods 0.000 description 5
206010020751 Hypersensitivity Diseases 0.000 description 4
230000001154 acute effect Effects 0.000 description 4
208000026935 allergic disease Diseases 0.000 description 4
210000000436 anus Anatomy 0.000 description 4
XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 4
230000009610 hypersensitivity Effects 0.000 description 4
230000002757 inflammatory effect Effects 0.000 description 4
230000000968 intestinal effect Effects 0.000 description 4
238000001543 one-way ANOVA Methods 0.000 description 4
238000005303 weighing Methods 0.000 description 4
208000007848 Alcoholism Diseases 0.000 description 3
206010002091 Anaesthesia Diseases 0.000 description 3
206010003591 Ataxia Diseases 0.000 description 3
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 3
CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 3
208000008469 Peptic Ulcer Diseases 0.000 description 3
229920005439 Perspex® Polymers 0.000 description 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 description 3
108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 description 3
206010044565 Tremor Diseases 0.000 description 3
201000007930 alcohol dependence Diseases 0.000 description 3
125000000217 alkyl group Chemical group 0.000 description 3
230000037005 anaesthesia Effects 0.000 description 3
238000004458 analytical method Methods 0.000 description 3
238000010171 animal model Methods 0.000 description 3
208000010643 digestive system disease Diseases 0.000 description 3
229960002986 dinoprostone Drugs 0.000 description 3
235000013305 food Nutrition 0.000 description 3
208000018685 gastrointestinal system disease Diseases 0.000 description 3
239000001257 hydrogen Substances 0.000 description 3
229910052739 hydrogen Inorganic materials 0.000 description 3
230000005764 inhibitory process Effects 0.000 description 3
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
229960005181 morphine Drugs 0.000 description 3
229960002009 naproxen Drugs 0.000 description 3
CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 3
CDBRNDSHEYLDJV-FVGYRXGTSA-M naproxen sodium Chemical compound [Na+].C1=C([C@H](C)C([O-])=O)C=CC2=CC(OC)=CC=C21 CDBRNDSHEYLDJV-FVGYRXGTSA-M 0.000 description 3
229960003940 naproxen sodium Drugs 0.000 description 3
201000008482 osteoarthritis Diseases 0.000 description 3
229920003023 plastic Polymers 0.000 description 3
239000004926 polymethyl methacrylate Substances 0.000 description 3
XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 description 3
238000007619 statistical method Methods 0.000 description 3
210000002784 stomach Anatomy 0.000 description 3
230000002195 synergetic effect Effects 0.000 description 3
239000003826 tablet Substances 0.000 description 3
230000009278 visceral effect Effects 0.000 description 3
OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 description 2
RDJGLLICXDHJDY-NSHDSACASA-N (2s)-2-(3-phenoxyphenyl)propanoic acid Chemical compound OC(=O)[C@@H](C)C1=CC=CC(OC=2C=CC=CC=2)=C1 RDJGLLICXDHJDY-NSHDSACASA-N 0.000 description 2
208000019901 Anxiety disease Diseases 0.000 description 2
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
208000024255 Audiogenic seizures Diseases 0.000 description 2
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
208000000094 Chronic Pain Diseases 0.000 description 2
206010017788 Gastric haemorrhage Diseases 0.000 description 2
208000007882 Gastritis Diseases 0.000 description 2
208000004547 Hallucinations Diseases 0.000 description 2
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
208000035154 Hyperesthesia Diseases 0.000 description 2
HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 2
241000699666 Mus <mouse, genus> Species 0.000 description 2
GQPLMRYTRLFLPF-UHFFFAOYSA-N Nitrous Oxide Chemical compound [O-][N+]#N GQPLMRYTRLFLPF-UHFFFAOYSA-N 0.000 description 2
206010033645 Pancreatitis Diseases 0.000 description 2
101100008035 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) CUE3 gene Proteins 0.000 description 2
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
NOSIYYJFMPDDSA-UHFFFAOYSA-N acepromazine Chemical compound C1=C(C(C)=O)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 NOSIYYJFMPDDSA-UHFFFAOYSA-N 0.000 description 2
229960005054 acepromazine Drugs 0.000 description 2
239000004480 active ingredient Substances 0.000 description 2
230000003502 anti-nociceptive effect Effects 0.000 description 2
230000036506 anxiety Effects 0.000 description 2
230000010397 anxiety-related behavior Effects 0.000 description 2
230000001977 ataxic effect Effects 0.000 description 2
239000011575 calcium Substances 0.000 description 2
229910052791 calcium Inorganic materials 0.000 description 2
239000002775 capsule Substances 0.000 description 2
125000004432 carbon atom Chemical group C* 0.000 description 2
235000020940 control diet Nutrition 0.000 description 2
201000003146 cystitis Diseases 0.000 description 2
229960001259 diclofenac Drugs 0.000 description 2
DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 2
229960000616 diflunisal Drugs 0.000 description 2
HUPFGZXOMWLGNK-UHFFFAOYSA-N diflunisal Chemical compound C1=C(O)C(C(=O)O)=CC(C=2C(=CC(F)=CC=2)F)=C1 HUPFGZXOMWLGNK-UHFFFAOYSA-N 0.000 description 2
201000010099 disease Diseases 0.000 description 2
239000002552 dosage form Substances 0.000 description 2
239000003937 drug carrier Substances 0.000 description 2
229960001419 fenoprofen Drugs 0.000 description 2
229960003692 gamma aminobutyric acid Drugs 0.000 description 2
239000007903 gelatin capsule Substances 0.000 description 2
210000003128 head Anatomy 0.000 description 2
229960001680 ibuprofen Drugs 0.000 description 2
208000027866 inflammatory disease Diseases 0.000 description 2
239000004615 ingredient Substances 0.000 description 2
239000007928 intraperitoneal injection Substances 0.000 description 2
229960003299 ketamine Drugs 0.000 description 2
230000002045 lasting effect Effects 0.000 description 2
235000020888 liquid diet Nutrition 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
229960003464 mefenamic acid Drugs 0.000 description 2
HYYBABOKPJLUIN-UHFFFAOYSA-N mefenamic acid Chemical compound CC1=CC=CC(NC=2C(=CC=CC=2)C(O)=O)=C1C HYYBABOKPJLUIN-UHFFFAOYSA-N 0.000 description 2
239000000203 mixture Substances 0.000 description 2
230000017074 necrotic cell death Effects 0.000 description 2
239000000825 pharmaceutical preparation Substances 0.000 description 2
239000004033 plastic Substances 0.000 description 2
210000000664 rectum Anatomy 0.000 description 2
206010039073 rheumatoid arthritis Diseases 0.000 description 2
238000013223 sprague-dawley female rat Methods 0.000 description 2
238000013222 sprague-dawley male rat Methods 0.000 description 2
210000003699 striated muscle Anatomy 0.000 description 2
239000007929 subcutaneous injection Substances 0.000 description 2
238000010254 subcutaneous injection Methods 0.000 description 2
229960000894 sulindac Drugs 0.000 description 2
MLKXDPUZXIRXEP-MFOYZWKCSA-N sulindac Chemical compound CC1=C(CC(O)=O)C2=CC(F)=CC=C2\C1=C/C1=CC=C(S(C)=O)C=C1 MLKXDPUZXIRXEP-MFOYZWKCSA-N 0.000 description 2
238000001356 surgical procedure Methods 0.000 description 2
208000011580 syndromic disease Diseases 0.000 description 2
239000008399 tap water Substances 0.000 description 2
235000020679 tap water Nutrition 0.000 description 2
238000011870 unpaired t-test Methods 0.000 description 2
230000000007 visual effect Effects 0.000 description 2
IUVMAUQEZFTTFB-UHFFFAOYSA-N 2-[1-(aminomethyl)-3,4-dimethylcyclopentyl]acetic acid Chemical compound CC1CC(CN)(CC(O)=O)CC1C IUVMAUQEZFTTFB-UHFFFAOYSA-N 0.000 description 1
UOPIILYKLVDKTK-UHFFFAOYSA-N 2-[1-(aminomethyl)-3-methylcyclohexyl]acetic acid Chemical compound CC1CCCC(CN)(CC(O)=O)C1 UOPIILYKLVDKTK-UHFFFAOYSA-N 0.000 description 1
HYVKVSAZCPKHDV-UHFFFAOYSA-N 2-[1-(aminomethyl)-3-methylcyclopentyl]acetic acid Chemical compound CC1CCC(CN)(CC(O)=O)C1 HYVKVSAZCPKHDV-UHFFFAOYSA-N 0.000 description 1
BSYNRYMUTXBXSQ-FOQJRBATSA-N 59096-14-9 Chemical compound CC(=O)OC1=CC=CC=C1[14C](O)=O BSYNRYMUTXBXSQ-FOQJRBATSA-N 0.000 description 1
229920001817 Agar Polymers 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
206010002556 Ankylosing Spondylitis Diseases 0.000 description 1
241001474374 Blennius Species 0.000 description 1
206010006811 Bursitis Diseases 0.000 description 1
229920000623 Cellulose acetate phthalate Polymers 0.000 description 1
229920002261 Corn starch Polymers 0.000 description 1
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
238000008157 ELISA kit Methods 0.000 description 1
239000001856 Ethyl cellulose Substances 0.000 description 1
ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
208000012671 Gastrointestinal haemorrhages Diseases 0.000 description 1
206010018001 Gastrointestinal perforation Diseases 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
201000005569 Gout Diseases 0.000 description 1
206010018634 Gouty Arthritis Diseases 0.000 description 1
208000032843 Hemorrhage Diseases 0.000 description 1
206010020565 Hyperaemia Diseases 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
206010061218 Inflammation Diseases 0.000 description 1
206010065390 Inflammatory pain Diseases 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
206010050953 Lower gastrointestinal haemorrhage Diseases 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
241000422980 Marietta Species 0.000 description 1
SBDNJUWAMKYJOX-UHFFFAOYSA-N Meclofenamic Acid Chemical compound CC1=CC=C(Cl)C(NC=2C(=CC=CC=2)C(O)=O)=C1Cl SBDNJUWAMKYJOX-UHFFFAOYSA-N 0.000 description 1
241001529936 Murinae Species 0.000 description 1
102000003896 Myeloperoxidases Human genes 0.000 description 1
108090000235 Myeloperoxidases Proteins 0.000 description 1
208000001294 Nociceptive Pain Diseases 0.000 description 1
235000019483 Peanut oil Nutrition 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
239000004743 Polypropylene Substances 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
241000700157 Rattus norvegicus Species 0.000 description 1
206010041349 Somnolence Diseases 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
235000021355 Stearic acid Nutrition 0.000 description 1
208000007107 Stomach Ulcer Diseases 0.000 description 1
238000000692 Student's t-test Methods 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
208000000491 Tendinopathy Diseases 0.000 description 1
206010043255 Tendonitis Diseases 0.000 description 1
240000006474 Theobroma bicolor Species 0.000 description 1
208000025865 Ulcer Diseases 0.000 description 1
210000001015 abdomen Anatomy 0.000 description 1
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
208000038016 acute inflammation Diseases 0.000 description 1
230000006022 acute inflammation Effects 0.000 description 1
208000005298 acute pain Diseases 0.000 description 1
230000002730 additional effect Effects 0.000 description 1
239000008272 agar Substances 0.000 description 1
208000029650 alcohol withdrawal Diseases 0.000 description 1
239000000783 alginic acid Substances 0.000 description 1
235000010443 alginic acid Nutrition 0.000 description 1
229920000615 alginic acid Polymers 0.000 description 1
229960001126 alginic acid Drugs 0.000 description 1
150000004781 alginic acids Chemical class 0.000 description 1
229940124277 aminobutyric acid Drugs 0.000 description 1
230000036592 analgesia Effects 0.000 description 1
229940035676 analgesics Drugs 0.000 description 1
239000000730 antalgic agent Substances 0.000 description 1
230000001773 anti-convulsant effect Effects 0.000 description 1
230000003110 anti-inflammatory effect Effects 0.000 description 1
229940125681 anticonvulsant agent Drugs 0.000 description 1
239000001961 anticonvulsive agent Substances 0.000 description 1
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
230000003542 behavioural effect Effects 0.000 description 1
238000001574 biopsy Methods 0.000 description 1
208000034158 bleeding Diseases 0.000 description 1
230000000740 bleeding effect Effects 0.000 description 1
230000000903 blocking effect Effects 0.000 description 1
230000037396 body weight Effects 0.000 description 1
229960003655 bromfenac Drugs 0.000 description 1
ZBPLOVFIXSTCRZ-UHFFFAOYSA-N bromfenac Chemical compound NC1=C(CC(O)=O)C=CC=C1C(=O)C1=CC=C(Br)C=C1 ZBPLOVFIXSTCRZ-UHFFFAOYSA-N 0.000 description 1
HZFGMQJYAFHESD-UHFFFAOYSA-M bromfenac sodium Chemical compound [Na+].NC1=C(CC([O-])=O)C=CC=C1C(=O)C1=CC=C(Br)C=C1 HZFGMQJYAFHESD-UHFFFAOYSA-M 0.000 description 1
229960002716 bromfenac sodium Drugs 0.000 description 1
238000004364 calculation method Methods 0.000 description 1
239000007963 capsule composition Substances 0.000 description 1
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
239000001768 carboxy methyl cellulose Substances 0.000 description 1
239000000679 carrageenan Substances 0.000 description 1
235000010418 carrageenan Nutrition 0.000 description 1
229920001525 carrageenan Polymers 0.000 description 1
229940113118 carrageenan Drugs 0.000 description 1
210000004534 cecum Anatomy 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
229940081734 cellulose acetate phthalate Drugs 0.000 description 1
206010009887 colitis Diseases 0.000 description 1
239000003086 colorant Substances 0.000 description 1
208000018631 connective tissue disease Diseases 0.000 description 1
235000005687 corn oil Nutrition 0.000 description 1
239000002285 corn oil Substances 0.000 description 1
239000008120 corn starch Substances 0.000 description 1
235000012343 cottonseed oil Nutrition 0.000 description 1
239000002385 cottonseed oil Substances 0.000 description 1
125000004122 cyclic group Chemical group 0.000 description 1
125000000753 cycloalkyl group Chemical group 0.000 description 1
230000001120 cytoprotective effect Effects 0.000 description 1
230000008260 defense mechanism Effects 0.000 description 1
230000003111 delayed effect Effects 0.000 description 1
238000009792 diffusion process Methods 0.000 description 1
230000001079 digestive effect Effects 0.000 description 1
235000020188 drinking water Nutrition 0.000 description 1
239000003651 drinking water Substances 0.000 description 1
238000002567 electromyography Methods 0.000 description 1
238000013156 embolectomy Methods 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
206010015037 epilepsy Diseases 0.000 description 1
235000019325 ethyl cellulose Nutrition 0.000 description 1
229920001249 ethyl cellulose Polymers 0.000 description 1
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
229960005293 etodolac Drugs 0.000 description 1
XFBVBWWRPKNWHW-UHFFFAOYSA-N etodolac Chemical compound C1COC(CC)(CC(O)=O)C2=N[C]3C(CC)=CC=CC3=C21 XFBVBWWRPKNWHW-UHFFFAOYSA-N 0.000 description 1
210000000744 eyelid Anatomy 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
235000013355 food flavoring agent Nutrition 0.000 description 1
210000001156 gastric mucosa Anatomy 0.000 description 1
208000021302 gastroesophageal reflux disease Diseases 0.000 description 1
208000030304 gastrointestinal bleeding Diseases 0.000 description 1
210000001035 gastrointestinal tract Anatomy 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
230000000762 glandular Effects 0.000 description 1
239000011521 glass Substances 0.000 description 1
150000002431 hydrogen Chemical class 0.000 description 1
238000003384 imaging method Methods 0.000 description 1
230000006698 induction Effects 0.000 description 1
230000001939 inductive effect Effects 0.000 description 1
230000004968 inflammatory condition Effects 0.000 description 1
230000004054 inflammatory process Effects 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
230000000977 initiatory effect Effects 0.000 description 1
230000003993 interaction Effects 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
239000008101 lactose Substances 0.000 description 1
210000003041 ligament Anatomy 0.000 description 1
239000007788 liquid Substances 0.000 description 1
230000005923 long-lasting effect Effects 0.000 description 1
230000007774 longterm Effects 0.000 description 1
210000003750 lower gastrointestinal tract Anatomy 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
239000000463 material Substances 0.000 description 1
229960003803 meclofenamic acid Drugs 0.000 description 1
230000004973 motor coordination Effects 0.000 description 1
210000003205 muscle Anatomy 0.000 description 1
210000005036 nerve Anatomy 0.000 description 1
208000004296 neuralgia Diseases 0.000 description 1
208000021722 neuropathic pain Diseases 0.000 description 1
229910001120 nichrome Inorganic materials 0.000 description 1
229910052757 nitrogen Inorganic materials 0.000 description 1
239000001272 nitrous oxide Substances 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
230000001473 noxious effect Effects 0.000 description 1
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
239000003921 oil Substances 0.000 description 1
235000019198 oils Nutrition 0.000 description 1
239000004006 olive oil Substances 0.000 description 1
235000008390 olive oil Nutrition 0.000 description 1
230000003287 optical effect Effects 0.000 description 1
239000001301 oxygen Substances 0.000 description 1
229910052760 oxygen Inorganic materials 0.000 description 1
238000007427 paired t-test Methods 0.000 description 1
239000003182 parenteral nutrition solution Substances 0.000 description 1
230000001575 pathological effect Effects 0.000 description 1
239000000312 peanut oil Substances 0.000 description 1
239000008188 pellet Substances 0.000 description 1
208000011906 peptic ulcer disease Diseases 0.000 description 1
239000008024 pharmaceutical diluent Substances 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
229940124531 pharmaceutical excipient Drugs 0.000 description 1
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
239000008363 phosphate buffer Substances 0.000 description 1
239000006187 pill Substances 0.000 description 1
229960002702 piroxicam Drugs 0.000 description 1
QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
229920001155 polypropylene Polymers 0.000 description 1
239000011591 potassium Substances 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
229920001592 potato starch Polymers 0.000 description 1
239000000843 powder Substances 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
208000037920 primary disease Diseases 0.000 description 1
230000035945 sensitivity Effects 0.000 description 1
239000008159 sesame oil Substances 0.000 description 1
235000011803 sesame oil Nutrition 0.000 description 1
239000011734 sodium Substances 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
235000017557 sodium bicarbonate Nutrition 0.000 description 1
229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
239000007787 solid Substances 0.000 description 1
239000000600 sorbitol Substances 0.000 description 1
238000012453 sprague-dawley rat model Methods 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
239000008117 stearic acid Substances 0.000 description 1
230000000638 stimulation Effects 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
239000000126 substance Substances 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
235000000346 sugar Nutrition 0.000 description 1
150000008163 sugars Chemical class 0.000 description 1
239000000725 suspension Substances 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
201000004415 tendinitis Diseases 0.000 description 1
238000010998 test method Methods 0.000 description 1
229940124597 therapeutic agent Drugs 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
238000007492 two-way ANOVA Methods 0.000 description 1
231100000397 ulcer Toxicity 0.000 description 1
235000015112 vegetable and seed oil Nutrition 0.000 description 1
239000008158 vegetable oil Substances 0.000 description 1
239000002023 wood Substances 0.000 description 1
UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Epidemiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Addiction (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Psychiatry (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Plant Substances (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Indole Compounds (AREA)

NO20000786A 1997-08-20 2000-02-17 Anvendelse av GABA analoger og et ikke-steroidalt anti-inflammatorisk legemiddel for fremstilling av et medikament for forebyggelse og behandling av gastrointestinal skade NO327983B1 (no)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
US5675397P	1997-08-20	1997-08-20
US7479498P	1998-02-16	1998-02-16
US8293698P	1998-04-24	1998-04-24
PCT/US1998/017082 WO1999008671A1 (en)	1997-08-20	1998-08-18	Gaba analogs to prevent and treat gastrointestinal damage

Publications (3)

Publication Number	Publication Date
NO20000786D0 NO20000786D0 (no)	2000-02-17
NO20000786L NO20000786L (no)	2000-02-17
NO327983B1 true NO327983B1 (no)	2009-11-02

Family

ID=27369092

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20000786A NO327983B1 (no)	1997-08-20	2000-02-17	Anvendelse av GABA analoger og et ikke-steroidalt anti-inflammatorisk legemiddel for fremstilling av et medikament for forebyggelse og behandling av gastrointestinal skade

Country Status (25)

Country	Link
US (2)	US6242488B1 (is)
EP (1)	EP1009399B1 (is)
JP (1)	JP4681116B2 (is)
KR (2)	KR100609359B1 (is)
AT (1)	ATE461698T1 (is)
AU (2)	AU8668598A (is)
BR (1)	BR9812133A (is)
CA (1)	CA2297163C (is)
CO (1)	CO4960645A1 (is)
CY (1)	CY1109981T1 (is)
DE (1)	DE69841574D1 (is)
DK (1)	DK1009399T3 (is)
ES (1)	ES2341154T3 (is)
HU (1)	HUP0004551A3 (is)
IL (1)	IL134164A (is)
IS (1)	IS2749B (is)
MY (1)	MY155223A (is)
NO (1)	NO327983B1 (is)
NZ (1)	NZ502729A (is)
PE (1)	PE107299A1 (is)
PL (1)	PL194125B1 (is)
PT (1)	PT1009399E (is)
TW (2)	TW570794B (is)
UY (1)	UY25148A1 (is)
WO (2)	WO1999008670A1 (is)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PL189872B1 (pl)	1996-07-24	2005-10-31	Warner Lambert Co	Zastosowanie izobutylogaby i jej pochodnych do wytwarzania leku do leczenia bólu
US6593368B2 (en)	1997-09-08	2003-07-15	Warner-Lambert Company	Analgesic compositions comprising anti-epileptic compounds and methods of using same
EP1031350A1 (en) *	1999-02-23	2000-08-30	Warner-Lambert Company	Use of a gabapentin-analog for the manufacture of a medicament for preventing and treating visceral pain
US6451857B1 (en)	1999-03-10	2002-09-17	Warner-Lambert Company	Analgesic compositions comprising anti-epileptic compounds and methods of using same
US6992109B1 (en) *	1999-04-08	2006-01-31	Segal Catherine A	Method for the treatment of incontinence
WO2000061188A1 (en) *	1999-04-09	2000-10-19	Euro-Celtique S.A.	Sodium channel blocker compositions and the use thereof
EP1840117A1 (en) *	1999-06-10	2007-10-03	Warner-Lambert Company LLC	Mono- and disubstituted 3-propyl gamma-aminobutyric acids
PT1202725E (pt)	1999-07-22	2007-07-11	Universuty Of Rochester	Método para tratar sintomas de alteração hormonal, incluindo afrontamentos.
FR2801217B1 (fr) *	1999-11-24	2002-12-06	Aventis Pharma Sa	Association de riluzole et de gabapentine et son utilisation comme medicament
JP2003533223A (ja) *	2000-05-16	2003-11-11	ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー	α２δ２カルシウムチャネルサブユニットの発現細胞株
EP1343805A4 (en)	2000-10-06	2005-07-20	Xenoport Inc	COMPOUNDS DERIVED FROM GALLENIC ACIDS FOR THE PROVISION OF CONTINUING SYSTEMIC CONCENTRATIONS OF MEDICINAL PRODUCTS AFTER ORAL ADMINISTRATION
US6900192B2 (en)	2000-10-06	2005-05-31	Xenoport, Inc.	Bile-acid conjugates for providing sustained systemic concentrations of drugs
EP1226820A1 (en) *	2001-01-26	2002-07-31	Warner-Lambert Company	Use of bicyclic amino acids for preventing and treating visceral pain and gastrointestinal disorders
EP1404324B2 (en)	2001-06-11	2011-04-06	XenoPort, Inc.	Prodrugs of gaba analogs, compositions and uses thereof
US7186855B2 (en)	2001-06-11	2007-03-06	Xenoport, Inc.	Prodrugs of GABA analogs, compositions and uses thereof
US6818787B2 (en)	2001-06-11	2004-11-16	Xenoport, Inc.	Prodrugs of GABA analogs, compositions and uses thereof
JP2005501013A (ja)	2001-06-11	2005-01-13	ゼノポート，インコーポレイテッド	Ｇａｂａ類似体の全身濃度が持続するアミノ酸コンジュゲート
US8048917B2 (en)	2005-04-06	2011-11-01	Xenoport, Inc.	Prodrugs of GABA analogs, compositions and uses thereof
AU2002333374B2 (en)	2001-09-03	2007-03-22	Newron Pharmaceuticals S.P.A.	Pharmaceutical composition comprising gabapentin or an analogue thereof and an (alpha)- aminoamide and its analgesic use
TWI312285B (en)	2001-10-25	2009-07-21	Depomed Inc	Methods of treatment using a gastric retained gabapentin dosage
US20060159743A1 (en) *	2001-10-25	2006-07-20	Depomed, Inc.	Methods of treating non-nociceptive pain states with gastric retentive gabapentin
US7612112B2 (en)	2001-10-25	2009-11-03	Depomed, Inc.	Methods of treatment using a gastric retained gabapentin dosage
US20070184104A1 (en) *	2001-10-25	2007-08-09	Depomed, Inc.	Gastric retentive gabapentin dosage forms and methods for using same
AU2002316231A1 (en)	2002-02-19	2003-09-29	Xenoport, Inc.	Methods for synthesis of prodrugs from 1-acyl-alkyl derivatives and compositions thereof
AU2003246864A1 (en) *	2002-02-22	2003-09-09	Warner-Lambert Company Llc	Combinations of an alpha-2-delta ligand with a selective inhibitor of cyclooxygenase-2
AU2003222033A1 (en)	2002-03-20	2003-10-08	Xenoport	Cyclic 1-(acyloxy)-alkyl prodrugs of gaba analogs, compositions and uses thereof
WO2003099338A2 (en)	2002-05-17	2003-12-04	Xenoport, Inc.	Amino acid conjugates providing for sustained systemic concentrations of gaba analogues
AU2003247042A1 (en) *	2002-07-10	2004-02-02	Warner-Lambert Company Llc	Gastrointestinal compositions comprising gaba derivatives
US7025745B2 (en) *	2002-10-07	2006-04-11	Advanced Cardiovascular Systems, Inc.	Method of making a catheter balloon using a tapered mandrel
US7473432B2 (en) *	2002-10-11	2009-01-06	Idea Ag	NSAID formulations, based on highly adaptable aggregates, for improved transport through barriers and topical drug delivery
WO2004052360A1 (en)	2002-12-11	2004-06-24	Xenoport, Inc.	Prodrugs of fused gaba analogs, pharmaceutical compositions and uses thereof
CA2451267A1 (en) *	2002-12-13	2004-06-13	Warner-Lambert Company Llc	Pharmaceutical uses for alpha2delta ligands
WO2004054560A1 (en) *	2002-12-13	2004-07-01	Warner-Lambert Company Llc	Alpha-2-delta ligand to treat lower urinary tract symptoms
MXPA05006209A (es) *	2002-12-13	2005-08-19	Warner Lambert Co	Pregabalina y sus derivados para el tratamiento de fibromialgia y otros trastornos relacionados.
WO2004078734A1 (en)	2003-03-07	2004-09-16	Warner-Lambert Company Llc	TETRAZOLE AND OXADIAZOLONE SUBSTITUTED β-AMINO ACID DERIVATIVES
WO2004084881A1 (en) *	2003-03-21	2004-10-07	Dynogen Pharmaceuticals, Inc.	METHODS FOR TREATING FUNCTIONAL BOWEL DISORDERS USING α2δ SUBUNIT CALCIUM CHANNEL MODULATORS WITH SMOOTH MUSCLE MODULATORS
US20050043407A1 (en) *	2003-08-22	2005-02-24	Pfizer Inc	Pharmaceutical composition for the prevention and treatment of addiction in a mammal
US7700652B2 (en)	2003-09-11	2010-04-20	Xenoport, Inc.	Treating urinary incontinence using prodrugs of GABA analogs
EP1677812A4 (en)	2003-09-17	2010-03-24	Xenoport Inc	TREATMENT OR PREVENTION OF NON-REST LEG SYNDROME USING GABA ANALOGUE-BASED PRODRUGS
BRPI0415288B8 (pt)	2003-10-14	2021-05-25	Xenoport Inc	composição farmacêutica compreendendo o ácido 1-{[(a- isobutanoiloxietoxi) carbonil] aminometil}- 1-ciclo- hexano acético cristalino
PL1691811T3 (pl)	2003-12-11	2014-12-31	Sunovion Pharmaceuticals Inc	Skojarzenie leku uspokajającego i modulatora neuroprzekaźnikowego oraz sposoby poprawy jakości snu i leczenia depresji
AU2005221401A1 (en) *	2004-03-12	2005-09-22	Warner-Lambert Company Llc	C1-symmetric bisphosphine ligands and their use in the asymmetric synthesis of pregabalin
WO2005095424A1 (en) *	2004-04-01	2005-10-13	Warner-Lambert Company Llc	Preparation of p-chirogenic phospholanes and their use in asymetric synthesis
DK1831154T3 (da)	2004-06-21	2010-04-12	Warner Lambert Co	Fremstilling af pregabalin og relaterede forbindelser
ATE471147T1 (de) *	2004-09-10	2010-07-15	Newron Pharm Spa	Verwendung von (r)-(halogenbenzyloxy)-benzylamino-propanamiden als natrium- und/oder calciumkanal- selektive modulatoren
CN101068538A (zh)	2004-11-04	2007-11-07	什诺波特有限公司	加巴喷丁前体药物持续释放口服剂型
DK1963280T3 (en) *	2005-12-22	2015-12-14	Newron Pharm Spa	2-phenylethylamine derivatives by calcium and / or sodium channel
US20090176882A1 (en)	2008-12-09	2009-07-09	Depomed, Inc.	Gastric retentive gabapentin dosage forms and methods for using same
MX2009006080A (es) *	2006-12-08	2009-07-14	Xenoport Inc	Uso de profarmacos de analogos de gaba para el tratamiento de enfermedades.
CA2703472A1 (en) *	2007-10-26	2009-04-30	The Scripps Research Institute	Methods for treating substance dependence
EP2250148B1 (en)	2008-01-25	2016-08-17	XenoPort, Inc.	Crystalline form of calcium-salts of (3s)-aminomethyl-5-methyl-hexanoic acids and methods of use
WO2009094577A2 (en)	2008-01-25	2009-07-30	Xenoport, Inc.	Mesophasic forms of (3s)-aminomethyl-5-methyl-hexanoic acid prodrugs and methods of use
TWI380812B (zh)	2008-01-25	2013-01-01	Xenoport Inc	（３ｓ）-胺甲基-５-甲基己酸前藥之晶形及使用方法
EP2116618A1 (en)	2008-05-09	2009-11-11	Agency for Science, Technology And Research	Diagnosis and treatment of Kawasaki disease
AU2009302241B2 (en)	2008-10-08	2015-10-29	Xgene Pharmaceutical Inc.	GABA conjugates and methods of use thereof
MX347467B (es) *	2009-06-22	2017-04-26	Wyeth Llc	Comprimidos de ibuprofeno de sodio y procedimientos de fabricación de composiciones farmacéuticas que incluyen ibuprofeno de sodio.
WO2011141923A2 (en)	2010-05-14	2011-11-17	Lupin Limited	Improved synthesis of optically pure (s) - 3-cyano-5-methyl-hexanoic acid alkyl ester, an intermediate of (s)- pregabalin
WO2012059797A1 (en)	2010-11-04	2012-05-10	Lupin Limited	Process for synthesis of (s) - pregabalin
US9066853B2 (en)	2013-01-15	2015-06-30	Warsaw Orthopedic, Inc.	Clonidine compounds in a biodegradable fiber
EP2948139B1 (en)	2013-01-28	2019-06-12	Lopez, Hector, L.	Methods of improving tolerability, pharmacodynamics, and efficacy of b-alanine and use therefor
CN105997970A (zh) *	2015-12-16	2016-10-12	南昌大学	γ-氨基丁酸在制备胃粘膜保护剂中的应用
US10052296B2 (en)	2016-04-07	2018-08-21	Nevakar Inc.	Formulations for treating pain
US11547686B2 (en)	2017-10-03	2023-01-10	Nevakar Injectables Inc.	Acetaminophen pregabalin combinations and methods of treating pain
CN112424158A (zh)	2018-05-14	2021-02-26	昌郁医药公司	萘普生和普瑞巴林的1-(酰氧基)-烷基氨基甲酸酯药物缀合物的结晶形式

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
BE634102A (is)
DE1963925C3 (de)	1969-12-20	1975-07-10	Desitin-Werk, Carl Klinke Gmbh, 2000 Hamburg	Verfahren zur Herstellung von N hoch 3-Carbalkoxyderivaten des 5,5-Diphenylhydantoins
JPS54110334A (en)	1978-02-16	1979-08-29	Fuji Chem Ind Co Ltd	Novel compounded anodyne and antiiinflammatory agent
US4158581A (en)	1978-04-14	1979-06-19	Westinghouse Electric Corp.	Method of making magnetic component for direct current apparatus
JPS61221121A (ja)	1985-03-27	1986-10-01	Nitto Electric Ind Co Ltd	テ−プ製剤
US4694010A (en)	1985-08-16	1987-09-15	New York University	Anticonvulsant compositions and method
EP0346445A4 (en)	1987-12-22	1990-03-28	Ferkany John W	DEXTRORPHANE POTENTIALIZER FOR ANTISPASMODIC COMPOSITIONS AND METHODS.
AU9137091A (en)	1990-11-27	1992-06-25	Northwestern University	Gaba and l-glutamic acid analogs for antiseizure treatment
GB9108362D0 (en)	1991-04-18	1991-06-05	Radoslavov Alexander	A pharmaceutical composition suitable for alleviation of headaches,migraine and other painful conditions
WO1993023383A1 (en) *	1992-05-20	1993-11-25	Northwestern University	Gaba and l-glutamic acid analogs for antiseizure treatment
US5234929A (en)	1992-07-20	1993-08-10	William Chelen	Method of treating motion sickness with anticonvulsants and antitussive agents
JPH06100468A (ja)	1992-09-25	1994-04-12	Kibun Food Chemifa Co Ltd	徐放性組成物
US5321012A (en)	1993-01-28	1994-06-14	Virginia Commonwealth University Medical College	Inhibiting the development of tolerance to and/or dependence on a narcotic addictive substance
JPH06227969A (ja)	1993-02-02	1994-08-16	Masayasu Sugihara	薬品の腸溶性改善方法およびそれにより得られた薬品組成物
US5420270A (en)	1993-10-07	1995-05-30	G. D. Searle & Co.	Aryl substituted dibenzoxazepine compounds, pharmaceutical compositions and methods of use
US5352638A (en)	1994-02-22	1994-10-04	Corning Incorporated	Nickel aluminosilicate glass-ceramics
HUT76798A (en)	1994-09-02	1997-11-28	Univ Virginia Commonwealth	Composition alleviating pain, containing a non-narcotic analgesic and an analgesia enhancer
GB9420784D0 (en) *	1994-10-14	1994-11-30	Glaxo Group Ltd	Medicaments
CN1046199C (zh)	1994-12-13	1999-11-10	凌吉安	复方消炎止痛霜剂
WO1998007447A1 (en) *	1996-08-23	1998-02-26	Algos Pharmaceutical Corporation	Anticonvulsant containing composition for treating neuropathic pain
SE9603408D0 (sv) *	1996-09-18	1996-09-18	Astra Ab	Medical use
WO1998017627A1 (en) *	1996-10-23	1998-04-30	Warner-Lambert Company	Substituted gamma aminobutyric acids as pharmaceutical agents
US6127418A (en) *	1997-08-20	2000-10-03	Warner-Lambert Company	GABA analogs to prevent and treat gastrointestinal damage

1998
- 1998-07-29 WO PCT/US1998/015694 patent/WO1999008670A1/en unknown
- 1998-07-29 AU AU86685/98A patent/AU8668598A/en not_active Withdrawn
- 1998-08-18 PT PT98945758T patent/PT1009399E/pt unknown
- 1998-08-18 KR KR1020007001703A patent/KR100609359B1/ko not_active IP Right Cessation
- 1998-08-18 HU HU0004551A patent/HUP0004551A3/hu unknown
- 1998-08-18 PL PL98338705A patent/PL194125B1/pl not_active IP Right Cessation
- 1998-08-18 ES ES98945758T patent/ES2341154T3/es not_active Expired - Lifetime
- 1998-08-18 DE DE69841574T patent/DE69841574D1/de not_active Expired - Lifetime
- 1998-08-18 TW TW087113592A patent/TW570794B/zh not_active IP Right Cessation
- 1998-08-18 NZ NZ502729A patent/NZ502729A/xx not_active IP Right Cessation
- 1998-08-18 BR BR9812133-2A patent/BR9812133A/pt not_active Application Discontinuation
- 1998-08-18 KR KR1020057022543A patent/KR20050116168A/ko not_active Application Discontinuation
- 1998-08-18 AU AU92930/98A patent/AU9293098A/en not_active Abandoned
- 1998-08-18 DK DK98945758.5T patent/DK1009399T3/da active
- 1998-08-18 JP JP2000509411A patent/JP4681116B2/ja not_active Expired - Fee Related
- 1998-08-18 CA CA002297163A patent/CA2297163C/en not_active Expired - Lifetime
- 1998-08-18 WO PCT/US1998/017082 patent/WO1999008671A1/en active IP Right Grant
- 1998-08-18 EP EP98945758A patent/EP1009399B1/en not_active Expired - Lifetime
- 1998-08-18 AT AT98945758T patent/ATE461698T1/de active
- 1998-08-18 IL IL13416498A patent/IL134164A/xx not_active IP Right Cessation
- 1998-08-18 TW TW092130045A patent/TWI251485B/zh not_active IP Right Cessation
- 1998-08-18 MY MYPI98003770A patent/MY155223A/en unknown
- 1998-08-19 CO CO98047372A patent/CO4960645A1/es unknown
- 1998-08-19 PE PE1998000745A patent/PE107299A1/es not_active Application Discontinuation
- 1998-08-20 UY UY25148A patent/UY25148A1/es unknown
2000
- 2000-01-25 IS IS5361A patent/IS2749B/is unknown
- 2000-02-17 NO NO20000786A patent/NO327983B1/no not_active IP Right Cessation
- 2000-05-09 US US09/567,191 patent/US6242488B1/en not_active Expired - Fee Related
2001
- 2001-03-13 US US09/804,742 patent/US6426368B2/en not_active Expired - Fee Related
2010
- 2010-04-26 CY CY20101100368T patent/CY1109981T1/el unknown

Also Published As

Publication number	Publication date
CO4960645A1 (es)	2000-09-25
TWI251485B (en)	2006-03-21
TW570794B (en)	2004-01-11
WO1999008670A1 (en)	1999-02-25
IL134164A (en)	2005-05-17
EP1009399A1 (en)	2000-06-21
TW200412938A (en)	2004-08-01
KR20010023084A (ko)	2001-03-26
WO1999008671A1 (en)	1999-02-25
PL194125B1 (pl)	2007-04-30
CA2297163C (en)	2001-11-20
EP1009399B1 (en)	2010-03-24
AU8668598A (en)	1999-03-08
UY25148A1 (es)	1999-01-26
DE69841574D1 (de)	2010-05-06
AU9293098A (en)	1999-03-08
IS2749B (is)	2011-08-15
ATE461698T1 (de)	2010-04-15
KR20050116168A (ko)	2005-12-09
HUP0004551A3 (en)	2002-11-28
KR100609359B1 (ko)	2006-08-04
NO20000786D0 (no)	2000-02-17
NO20000786L (no)	2000-02-17
US6426368B2 (en)	2002-07-30
US20010014698A1 (en)	2001-08-16
PT1009399E (pt)	2010-05-21
DK1009399T3 (da)	2010-05-31
CA2297163A1 (en)	1999-02-25
PE107299A1 (es)	1999-12-19
ES2341154T3 (es)	2010-06-15
JP2001515033A (ja)	2001-09-18
BR9812133A (pt)	2000-07-18
HUP0004551A2 (hu)	2001-05-28
IS5361A (is)	2000-01-25
IL134164A0 (en)	2001-04-30
PL338705A1 (en)	2000-11-20
MY155223A (en)	2015-09-30
US6242488B1 (en)	2001-06-05
CY1109981T1 (el)	2014-09-10
JP4681116B2 (ja)	2011-05-11
NZ502729A (en)	2002-10-25

Legal Events

Date	Code	Title	Description
2013-03-25	MM1K	Lapsed by not paying the annual fees

Publication	Publication Date	Title
NO327983B1 (no)	2009-11-02	Anvendelse av GABA analoger og et ikke-steroidalt anti-inflammatorisk legemiddel for fremstilling av et medikament for forebyggelse og behandling av gastrointestinal skade
US6127418A (en)	2000-10-03	GABA analogs to prevent and treat gastrointestinal damage
CN1109543C (zh)	2003-05-28	包括二十碳五烯酸和/或十八碳四烯酸的药物制剂
Chojnacki et al.	2011	Evaluation of melatonin effectiveness in the adjuvant treatment of ulcerative colitis
ES2582376T3 (es)	2016-09-12	Método para la mejora de la señalización de islotes en diabetes mellitus y para su prevención
JP4452255B2 (ja)	2010-04-21	炎症性疾患の処置用医薬の製造におけるガバ類縁体、たとえばガバペンチンの使用
RU2389500C2 (ru)	2010-05-20	Нейропротективная пищевая добавка
Tarrerias et al.	2002	Short-chain fatty acid enemas fail to decrease colonic hypersensitivity and inflammation in TNBS-induced colonic inflammation in rats
FR2559061A1 (fr)	1985-08-09	Compositions analgesiques et anti-inflammatoires contenant de la diphenhydramine
FR2530469A1 (fr)	1984-01-27	Composition analgesique et anti-inflammatoire contenant de la cafeine
EP0974351A2 (en)	2000-01-26	Medicament for preventing and treating gastrointestinal damage
EP1221950A1 (en)	2002-07-17	Synergistic combinations of an nk 1? receptor antagonist and a gaba structural analog
US8728546B1 (en)	2014-05-20	Medicament for treatment of cancer, cardiovascular diseases and inflammation
Wang et al.	2020	Opening a window on attention: adjuvant therapies for inflammatory bowel disease
AU2002317548B2 (en)	2006-02-23	Gaba analogs to prevent and treat gastrointestinal damage
US9155704B1 (en)	2015-10-13	More palatable, bioequivalent pharmaceutical composition of carprofen
MXPA00001093A (en)	2001-03-05	Gaba analogs to prevent and treat gastrointestinal damage
BR112020018533A2 (pt)	2020-12-29	Preparação farmacêutica ou de suplemento alimentar com base sobre alfa-lactalbumina
FR3077201A1 (fr)	2019-08-02	Derives aminoacides contenant un groupement disulfanyle sous forme d'un inhibiteur de nep et d'apn pour la prevention et le traitement des douleurs relatives au nerf trijumeau
Enders et al.	2023	Lifestyle and Dietary Modifications: Relevance in the Management of Diabetic Neuropathy
EP3883557A1 (en)	2021-09-29	Composition for use in the prevention and/or symptomatic treatment of irritable bowel syndrome
JPH0465049B2 (is)	1992-10-16
DeLegge et al.	2008	Nutrition in Inflammatory Bowel Disease
JP2004315497A (ja)	2004-11-11	リポポリサッカライドを有効成分とする肛門圧低下外用剤
FR2741264A1 (fr)	1997-05-23	Composition contenant de l'acide mefenamique en association avec de la codeine